Cassava Sciences Inc. (NASDAQ:SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company’s trial for simufilamFollowing previously reported communications with the FDA regarding Cassava’s investigational new drug application and proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex (TSC)-related epilepsy, the company confirmed a full FDA clinical hold.The SEC filing highlighted that the company has to provide the FDA with additional ...

Let's continue the conversation right here with Toron Slack. He's chief economist at Apollo Global Management. Um, you have a favorite in that Fed race, by the way.Well, so I don't have a personal favorite, but I think it's clear that the market is trying to chew hard on which of these candidates will have implications for what's happening, especially of course in rates. What the conclusion of course here is that it all becomes about can the new fetcher persuade the other FOMC members about whatever his vie ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

We're back on Morning Trade Live. So, let's focus on Nike right now. The stock is selling off today after issuing a very gloomy outlaw.For more on that in a second, today's move on the chart is just the latest in a very up and down year. 6 months ago, the stock gapped up 15% after earnings and was trading as high as 80 bucks in late August, but since Labor Day, the stock is down more than 25%. And that is after today's slide.So, we are down right now. We're at 59 in change. Let's take a look at other athlei ...

Aspo Plc ANNOUNCEMENT 19.12.2025 Aspo Plc: Share repurchase 19.12.2025 In the Helsinki Stock Exchange Trade date 19.12.2025 Bourse trade Buy Share ASPO Amount 3 000SharesAverage price/ share 6,5067EURTotal cost 19 520,10EUR Aspo Plc now holds ...

The Alerian MLP ETF (NYSEARCA:AMLP) offers retirees an 8.75% dividend yield by investing in master limited partnerships that own energy infrastructure assets like pipelines, storage facilities, and processing plants. ...

Palantir (PLTR) has been riding the AI boom front and center for the last couple of years now, and outspoken CEO Alex Karp has been promising to defy legacy skepticism and reward true believers with epic financial results every step of the way. Karp’s holiday message in 2024 was incredibly bold to say the least. He thanked all the bulls who shunned Wall Street’s “rusty, crusty platitudes.” No slide deck, and no numbers. Karp just made a clear point about belief over consensus, and vision over noise. Mor ...

Gold prices are broadly flat in afternoon trading but set to close the week in positive territory."Persistent demand continues to underpin prices, with ongoing purchases by central banks and resilient ETF inflows," says Milad Azar of XTB MENA, while "geopolitical tensions remain a key supportive pillar."The latest U.S. inflation data came in below expectations, sparking a rally on Wall Street Thursday, but economists cautioned against reading too much into the report because of gaps in data collection durin ...

Core Viewpoint - Tesla's stock is experiencing volatility due to competition in the electric vehicle (EV) market and execution risks related to its autonomous vehicle roadmap, leading to reassessment of growth expectations by investors [1][2]. Group 1: Market Dynamics - Tesla's stock has fluctuated this week, reflecting investor concerns over growth amid competition and execution risks [1][2]. - The broader technology sector, particularly the "Magnificent Seven," has seen profit-taking, impacting Tesla's stock as investors question high valuations driven by artificial intelligence enthusiasm [3]. - Tesla's US market share has decreased from 52.7% in 2024 to 43.2% in Q1 2025, with BYD leading the global market at 15.4%, which pressures Tesla's pricing and margins [4]. Group 2: Operational Challenges - Analysts have revised estimates, projecting a 10.5% decrease in volumes for 2026 and an 18.5% reduction in cumulative deliveries through 2040 due to slower EV adoption in mature markets and increased competition [5]. - Tesla recalled over 10,000 Powerwall 2 battery units in the US due to fire incidents, raising concerns about product quality and regulatory oversight [5]. - Investors are monitoring the potential removal of "safety monitors" from Model Y robotaxis, as delays could indicate challenges in executing the autonomous driving roadmap [6]. Group 3: Analyst Sentiment - Morgan Stanley downgraded Tesla from Buy to Hold, citing valuation concerns and lower delivery expectations, indicating skepticism about the stock's ability to achieve significant upside without operational breakthroughs [7]. - Some analysts remain optimistic about Tesla's robotaxi potential, with expectations to expand to eight to ten metropolitan areas by the end of 2025 [9]. - The analyst consensus is divided, with some viewing current weakness as a buying opportunity for long-term investors in AI and autonomy, while others caution against a slowdown in delivery growth [10].

PresentationThank you for standing by. My name is Jayel, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin business update. [Operator Instructions] I would now like to turn the conference over to Traci McCarthy, Head of Investor Relations. You may begin. Perhaps, your line is on mute, Traci.Traci McCartyGroup Vice President Thank you, Jayel, and good morning, everyone. Thank you for joining us to discuss BioMarin's acquisition of Amicus Therapeutics ...